Risk of osteoporotic fractures in diabetic patients treated with glitazones;Riziko osteoporotických fraktúr u diabetikov liečených glitazónmi

Osteologicky Bulletin

Volumn 15, Issue 2, 2010, Pages 57-60

  Payer, Juraj ^a   Jackuliak, P ^a   Killinger, Z ^a  

^a V interná klinika LF UK a UN Bratislava Nemocnica Ru inov   (Slovakia)

Author keywords

Fractures; Glitazones; Osteoporosis; PPAR gamma

Indexed keywords

GLITAZONE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

CELL DIFFERENTIATION; DIABETIC PATIENT; DRUG MECHANISM; FRAGILITY FRACTURE; HEMATOPOIETIC CELL; HIGH RISK POPULATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOBLAST; OSTEOCLAST; OSTEOPOROSIS; REVIEW;

EID: 77955615613     PISSN: 12113778     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Blahoš J. Osteoporóza. Praha, Galén, 1995; p 172.
2. Mokáň M. Epidemiológia diabetes mellitus. In: Mokáň M., Martinka E., Galajda P. et al. Diabetes mellitus a vybranné metabolické ochorenia. Martin, Vyd. P+M, 2008; p 1003.
3. Ivers RQ, Cumming RG, Mitchell P, Peduto AJ. Diabetes and risk of fracture: The Blue Mountains Eye Study. Diabetes Care 2001;24:1198-1203.
4. Palička V. Léky ovlivňující kostní metabolizmus diabetiků. Vnitř Lék 2009,55:368-370.
5. Schwartz AV, Sellmeyer DE. Women, type 2 diabetes, and fracture risk. Curr Diab Rep 2004;4:364-369,
6. Marcus R, Feldman D, Nelson D, Rosen C. Osteoporosis 3rd Edition. Elsevier 2008.
7. Brown SA, Sharpless JL. Osteoporosis: An Under-appreciated Complication of Diabetes. Clinical Diabetes 2004;22:10-19.
8. Rovenstý J, Payer J, Calgue RB. Dictionary of Rheumatology. Wien, Springer-Verlag 2009; p 230.
9. Payer J, Rovenstý J, Killinger Z. Lexikón osteoporózy. Bratislava, SAP - Slovak Academic Press, s.r.o., 2007; p 75.
10. Ochodnický M. Vybrané metabolické ochorenia. In: Mokáň M., Martinka E., Galajda P. et al. Diabetes mellitus a vybranné metabolické ochorenia. Martin, Vyd. P+M, 2008; p 1003.
11. Greenfield JR. Chischolm DJ. Thiazolidinediones - mechanism of action. Austr Prescr 2004;27:67-70.
12. Maclsaac RJ. Jerums G. Clinical indications for thiazolidinediones. Austr Prescr 2004; 27:70-74.
13. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-1018.
14. Uličlansky V. Algoritmus liečby diabetes mellitus 2. typu. Prešov, Diabetol s.r.o, 2009; p 285.
15. Parulkar AA. Pendergrass ML. Granda-Ayala R. Lee TR. Fonseca VA. Nonhypoglycemic effects of Thiazolidinediones. Ann Intern Med 2001; 134:61-71.
16. Schoonjans K, Auwerx J. Thiazolidinediones: an update. Lancet 2000;355: 1008-1010.
17. Grey A. Skeletal consequences of tbiazolidinedione therapy. Osteoporosis Int 2008; 19:129-137.
18. Wan Y, Chong LW, Evans RM. PPAR-gamma regulates osteoclastogenesis in mice. Nat Med 2007;13:1496-1503.
19. Rosen CJ, Bouxsein ML. Mechanism of disease: is osteoporosis the obesity of bone? Natur Clinical Practice Rheumatology 2006;2:35-43.
20. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin or glyburide monotherapy. New Engl J Med 2006;355:2427-2443.
21. Kahn SE, Zinman B, Lachin JM et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008;31:845-851.
22. Holmberg AH, Nilsson J-Å, Åkesson K. The association between hyperglycemia and fracture risk in middle age. A prospective population-based study of 22.444 men and 10.902 women. J Clin Endocrinol Metab 2008;93.815-822.
23. Meier C, Kraenzlin ME, Bodmer M et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008;168:820-825.
24. Habib ZA, Havstad SL, Wells K et al. Thiazolidinedione Use and the Longitudinal Risk of Fractures in Patients with Type 2 Diabetes Mellitus. J Clin Endcorinol Metab 2010; 95:592-600.
25. Hsiao F-Y, Mullins CD. The association between thiazolidinediones and hospitalisation for fracture in type 2 diabetic patients: a Taiwanese population-based nested case-control study. Diabetologia 2010;53:489-496.
26. Yaturu S, Bryant B, Jain SK. Thiazolidinediones treatment decrease bone mineral density in type 2 diabetic men. Diabetes Care 2007; 30: 1574-1576. (Pubitemid 46876524)
27. Sanders KM, Seeman E, Ugoni AM et al. Age- and gender-specific rate of fractures in Australia: a population-based study. Osteoporosis Int 1999; 10:240-247. (Pubitemid 29458720)
28. Loke Y, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009;180:32-39.
29. Maclsaac RJ. Jerums G. Clinical indications for thiazolidinediones. Austr Prescr 2004; 27:70-74.
30. Delea TZ, Edelsberg JS, Hagiwara M, Oster G, Phillips LS. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes. Diabetes Care 2003;26:2983-2989.
31. National Collaborating Centre for Chronic Conditions. Type 2 diabetes: national clinical guideline for management in primary and secondary care (update). London 2008: Royal College of Physicians.